Last reviewed · How we verify

NCT04242329: SUMMIST

Surgery of Melanoma Metastases After Systemic Therapy

Withdrawn Phase 2 Last updated 26 January 2024
What this trial tests

Phase 2 trial testing Surgical metastasectomy in Melanoma. Withdrawn.

Timeline
11 March 2021
Primary endpoint
3 September 2023
13 September 2023

Quick facts

Lead sponsorVastra Gotaland Region
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Start date11 March 2021
Primary completion3 September 2023
Estimated completion13 September 2023
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Vastra Gotaland Region — full company profile →

Who can join

18 and older, any sex, with Melanoma or Melanoma Stage IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate if surgical removal of residual disease adds benefit in stage IV melanoma patients with partial response or stable disease after a minimum 9 months of first-line PD-1 inhibition. Primary endpoint: Disease-free survival (DFS) at 12 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Surgical metastasectomy

Trials testing the same drug.

Other recruiting trials for Melanoma

Currently open trials in the same condition.

Other Vastra Gotaland Region trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04242329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing